<DOC>
	<DOCNO>NCT02371148</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design determine efficacy safety Bortezomib plus Rituximab plus Bendamustine patient relapsed/refractory Waldenstrom 's Macroglobulinemia .</brief_summary>
	<brief_title>Fase II Study With BRB Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia 's</brief_title>
	<detailed_description>The progression free survival ( PFS ) expect lymphoplasmacytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia characteristic indicate study treat standard Rituximab plus chemotherapy may estimate 50 % 18 month . The Investigators would consider positive result increase 18 months-PFS rate 50 65 % .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histological proven diagnosis Lymphoplasmacytic/cytoid lymphoma/Waldenstrom macroglobulinemia accord REAL/WHO Classification Relapsed/refractory disease receive one line chemotherapy ( rituximab ) . If patient receive bortezomib bendamustine obtain partial response last least two year . Age &gt; = 18 Presence least one follow criterion definition active disease : Systemic symptom Hemoglobin le 10 g/dL ( due lymphoma ) Platelets less 100 x 109/L ( due lymphoma ) symptomatic splenomegaly Bulky disease ( &gt; 7 cm ) Hyperviscosity syndrome , peripheral neuropathy grade 1 ( Waldenstrom 's diseaserelated ) , hemolytic anemia , immune complex vasculitis Life expectancy &gt; 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 02 leave ventricular ejection fraction ( LVEF ) ≥45 % FS ≥37 % Creatinine 1.5 x upper limit normal Conjugated bilirubin 2 x upper limit normal Alkaline phosphatase transaminases 2 x upper limit normal Written inform content Patients receive bortezomib bendamustine firstline therapy , n't obtain least partial response partial response last least two year . Patients agree take adequate contraceptive precaution least 6 month cessation therapy History malignancy within 3 year prior study entry except : adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage , localized prostate cancer treat surgically curative intent ; good prognosis ductal carcinoma situ ( DCIS ) breast treated lumpectomy alone curative intent Medical condition require long term use ( &gt; 1 month ) systemic corticosteroid Active bacterial , viral , fungal infection require systemic therapy Peripheral neuropathy grade ≥ 2 [ see Appendix Section A ] Concurrent medical condition might exclude administration therapy Cardiac insufficiency ( NYHA grade III/IV ) Myocardial infarction within 6 month entry study Severe chronic obstructive pulmonary disease hypoxemia Severe diabetes mellitus difficult control adequate insulin therapy Hypertension difficult control Impaired renal function creatinine clearance &lt; 30 ml/min HIV positivity HBV positivity exception patient HbsAg HBVDNA negative Ab antiHB core positive ( patient need receive prophylaxis Lamivudine ) HCV positivity exception patient HCV RNA negative Participation time another study investigational drug use Known hypersensitivity anaphylactic reaction murine antibody proteins Any coexist medical psychological condition would preclude participation study compromise ability give inform consent . Women pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>